



Andrew I. Chin, M.D.

Clinical Interests	Dr. Chin is interested in the care of those with kidney diseases. This includes individuals with chronic kidney disease, inflammatory kidney conditions, as well as adults on long-term dialysis. He also devotes much of his time to the education and training of residents and fellows.
Research/Academic Interests	Dr. Chin's research focuses on clinical aspects of dialysis, including vascular access and dialysis treatment adequacy, as well as the progression of chronic kidney disease.
Title	Professor, Health Science
Specialty	Internal Medicine, Nephrology
Department	Internal Medicine
Division	Nephrology
Address/Phone	Lawrence J. Ellison Ambulatory Care Center, Nephrology Clinic, 4860 Y St. Suite 0200 Sacramento, CA 95817 Phone: 916-734-3761
Additional Phone	Physician Referrals: 800-4-UCDAVIS (800-482-3284)
Education	M.D., UC Davis School of Medicine, Sacramento CA 1995 B.A., Princeton University, Princeton NJ 1991
Internships	Internal Medicine, Scripps Mercy Hospital and Medical Center, San Diego CA 1995-1996
Residency	Internal Medicine, Scripps Mercy Hospital and Medical Center, San Diego CA 1996-1998 Chief Resident - Internal Medicine, Scripps Mercy Hospital and Medical Center, San Diego CA 1998-1999
Fellowships	Nephrology, UC Davis Medical Center, Sacramento CA 1999-2001
Board Certifications	American Board of Internal Medicine American Board of Internal Medicine, Nephrology
Honors and Awards	Resident of the Year, Teaching Award, Scripps Mercy Hospital and Medical Center, 1998
Select Recent Publications	Wang J, Nguyen TA, Chin AI, Ross JL. Treatment of tunneled dialysis catheter malfunction: revision versus exchange. J Vascular Access. 2016.



Andrew I. Chin, M.D.

Chin AI, Nguyen TA, Dinesh KP, Morfin JA. Late acceleration of glomerular filtration rate decline is a risk for hemodialysis catheter use in patients with established nephrology chronic kidney disease care. *Hemodial Int.* 2015 Jul;19(3):379-85.

Kaysen GA, Chin A. If oxidative stress is an appropriate and specific target, what reagent should we choose? *J Am Soc Nephrol.* 2014 Mar;25(3):427-9.

Chin AI, Dalrymple LS. Ideal cardiovascular health and progression of CKD: perhaps not so 'simple'. *J Am Soc Nephrol.* 2013 Jun;24(7):1031-3.

Chang DN, Dager WE, Chin AI. Removal of dabigatran by hemodialysis. *Am J Kidney Dis.* 2013 Mar;61(3):487-9.

Chin AI, Raffo WR, Yang X, and Madison JR. Evolution of hemodialysis access resistance: a longitudinal 5-year model using functional principal components analysis. *Int J Artif Organs.* 2009; 32(12):864-71.

Chin AI Renal acid-base balance and renal tubular acidosis, Chapter In: *Urinary Stone Disease: the practical guide to medical and surgical management.* Ed. By Stoller and Meng. The Humana Press, Inc., 2007.

Chin AI and Yeun JY. Encapsulating Peritoneal Sclerosis: An Unpredictable and Devastating Complication of Peritoneal Dialysis. *American Journal of Kidney Diseases.* 2006;47(4): 697-712.

Morfin JA and Chin AI. Urinary Oxalate Crystals in Ethylene Glycol Intoxication. *New England*



Andrew I. Chin, M.D.

Journal of Medicine. 2005;353(24), e21.

Chin AI, Chang W, Fitzgerald JT, Schanzer A, Perez RV, McVicar JP and Troppmann C. Intra-access blood flow in patients with newly created upper arm arteriovenous native fistulae for hemodialysis access. American Journal of Kidney Diseases. 2004;44(5):850-58.

© 2017 UC Regents